A R T I C L E S
Nwe et al.
Syntheses. 1,3-Bis[1-(4,7,10-tris(carbamoylmethyl)-1,4,7,10-
tetraazacyclododecane]-m-xylene (1). To 0.500 g (1.25 mmol)
of compound 6 (1,3-bis-(1,4,7,10-tetraazacyclododecane))30 was
added 1.04 g (7.54 mmol) of K2CO3 and 1.04 g (7.60 mmol) of
bromoacetamide in 30 mL of absolute ethanol. The solution was
stirred at 80 °C overnight under nitrogen. Solid K2CO3 was filtered
off, and the solvent was removed under vacuum. The residue was
dissolved in a minimum amount of methanol, and chloroform was
added. The supernatant was filtered off,and the resulting white
precipitate was dried under vacuum. Yield: 90%. ESI m/z: 789 (M
+ 1), 827 (M + K), 811 (M + Na). 1H NMR (500 MHz, D2O): δ
) 2.55-3.25 (44 H, m, ring CH2, NCH2CONH2), 4.2 (4H, s,
ArCH2N), 7.54 (2H, m, Ph), 7.45 (2H, m, Ph). 13C NMR (300 MHz,
D2O): δ ) 49.50, 50.85, 51.21, 51.76, 55.78, 56.3 (ring CH2 and
NCH2CONH2), 68.9 (ArCH2N), 130.8, 132.1, 134.0 (Ph), 175.2,
176.4 (CdO).
1,4-Bis[1-(4,7,10-tris(carbamoylmethyl)-1,4,7,10-tetraazacy-
clododecane]-p-xylene (2). A procedure similar to that described
for 1 was used to produce a white solid in 90% yield from
compound 7 (1,4-bis-(1,4,7,10-tetraazacyclododecane)).30 ESI m/z:
789 (M + 1), 827 (M + K). 1H NMR (500 MHz, D2O): δ )
2.45-3.15 (40 H, m, ring CH2, NCH2CONH2), 3.22 (s, 4H,
NCH2CONH2), 3.85 (s, 4H, NCH2Ar), 7.30 (s, 4H, Ph). 13C NMR
(300 MHz, D2O): δ ) 50.5, 51.3, 51.5, 52.3, 56.3, 57.0, 58.3 (ring
CH2 and NCH2CONH2 and ArCH2N), 130.8, 163.8 (Ph), 176.2,
177.2 (CdO).
1-[3′-(N,N-Diethylaminomethyl)benzyl]-4,7,10-tris(ter-butoxy-
carbonyl)-1,4,7,10-tetraazacyclododecane (9). An acetonitrile
solution containing 8 (1-[3′-(bromomethyl)benzyl]-4,7,10-tris(ter-
butoxycarbonyl)-1,4,7,10-tetraazacyclododecane)31 (1.00 g, 1.53
mmol) and diethylamine (200 µL, 2.08 mmol) was stirred at room
temperature for 6 h. The solvent was removed under vacuum. The
resulting crude product was washed with hexanes and dried twice
to obtain a pale yellow solid which was used without further
purification. Yield 90%. ESI m/z: 648 (M + 1). 1H NMR (500
MHz, CDCl3): δ ) 1.20 (6H, t, CH2CH3), 1.42 (18 H, m, CH3),
1.48 (9H, m, CH3), 2.65 (8H, m, ring CH2, CH2CH3), 3.2-3.81
(28H, m, ring CH2, ArCH2N, ArCH2N(CH2CH3)2), 7.22-7.4 (4H,
m, Ph). 13C NMR (300 MHz, CDCl3): δ ) 11.0 (CH2CH3) 29.0,
29.4 (CH3; t-but), 47.2 (CH2CH3), 48.4, 50.1, 55.1, 56.2, 57.5, 65.7,
72.8 (ring CH2 and ArCH2N(CH2CH3)2 and ArCH2N), 80.1
(C(CH3)3), 128.1, 129.3, 129.8, 130.4, 132.0, 137.5 (Ph), 156.0,
156.4, 156.8 (CdO).
Even more challenging than the study of mononuclear Eu(III)
complexes is the design and characterization of effective
dinuclear lanthanide ion catalysts. Our past work with self-
assembled dinuclear lanthanide catalysts containing a bridging
hydroxide ligand showed that there was little cooperativity
between metal ion centers for the cleavage of phosphate
diesters.28 Other reported self-assembled multinuclear lanthanide
complexes contain weakly bound ligands and bridging hydrox-
ides that lead to cooperative behavior of the two metal ion
centers toward phosphate diester cleavage.1,5 The fragile nature
of these highly reactive complexes makes it difficult to define
the solution speciation of these systems and to probe the
mechanism of catalytic cleavage.
Here we present studies of two dinuclear Eu(III) macrocyclic
complexes that have two coordination sites on each Eu(III) ion
center for catalysis. Cleavage of an RNA model, 2-hydroxypro-
pyl-4-nitrophenyl phosphate (HpPNP), and a dinucleoside,
uridylyl-3′,5′-uridine (UpU), by these dinuclear catalysts is
compared to their mononuclear analogues to gauge the extent
of lanthanide ion cooperativity in the dinuclear catalysts. These
comparisons are further illuminated by characterization of
solution speciation and Eu(III) complex binding to carbonate
and to phosphate esters that are substrate and transition state
analogues. Despite the lack of Ln(III) ion cooperativity in
catalysis, the tethered dinuclear lanthanide ion complexes
presented here are among the most active metal ion macrocyclic
catalysts for dinucleoside and RNA analogue cleavage in water
at 25 °C that have been reported to date. Direct excitation
luminescence spectroscopy provides a unique opportunity to
fully characterize the coordination properties of these active
catalysts including the surprising absence of hydroxide ligands
and the formation of bridging phosphate ester complexes.
Experimental Section
Cyclen (1,4,7,10-tetraazacyclododecane) was purchased from
Strem chemicals. Acetonitrile and methanol were dried over calcium
hydride. HpPNP,29 1,4,7-tris(carbamoylmethyl)-1,4,7,10-tetraza-
cyclododecane (5), and Eu(5) were prepared as reported earlier.16
1-[3′-(N,N-Diethylaminomethyl)benzyl]-1,4,7,10-tetraazacy-
clododecane (10). Compound 9 (1.00 g, 1.55 mmol) was dissolved
in 20 mL of ethanol, and 7 mL of concentrated hydrochloric acid
was slowly added. The solution was stirred at room temperature
for 8 h during which time a precipitate formed. The precipitate
was filtered, washed with ethanol, and dried. The dried hydrochlo-
ride salt was then dissolved in a minimum amount of water, and
the pH was adjusted to 12.5. The solution was extracted with
dichloromethane, and the organic layer was dried over anhydrous
sodium sulfate. The solvent was removed to yield a pale yellow
+
Uridylyl(3′,5′)uridine (UpU, NH4 salt), uridine (2′,3′)-cyclic
monophosphate (2′,3′-cUMP), uridine 3′-monophosphate (3′-UMP),
uridine 2′-monophosphate (2′-UMP), and uridine were reagent grade
from Sigma-Aldrich. Milli-Q purified water was boiled and bubbled
with nitrogen gas for 1 h prior to use in kinetic experiments or in
luminescence measurements to minimize carbonate concentrations.
An Orion research digital ionalyzer, model 510, equipped with a
temperature compensation probe was used for all pH measurements.
All 1H and 13C NMR were recorded on either a Gemini-300, Inova-
400, or Inova-500 spectrometer.
1
solid. (yield, 85%). ESI m/z: 348 (M + 1). H NMR (500 MHz,
D2O): δ ) 1.2 (6H, t, CH2CH3), 2.8-3.7 (24H, m, ring CH2,
CH2CH3), 3.9 (2H, s, ArCH2N), 4.2 (2H, s, ArCH2N(CH2CH3)2),
7.2-7.6 (4H, m, Ph). 13C NMR (300 MHz, D2O): δ ) 8.10
(NCH2CH3), 41.9 (NCH2CH3), 42.2, 43.8, 44.3, 46.9 (ring CH2),
55.7 56.5 (ArCH2N and ArCH2N(CH2CH3)2), 129.8, 130.1, 130.9,
131.7, 132.7, 135.3 (Ph).
(23) Brittain, H. G.; Mantha, S.; Tweedle, M. F. J. Less-Common Met.
1986, 126, 339–342.
(24) Hernandez, G.; Brittain, H. G.; Tweedle, M. F.; Bryant, R. G. Inorg.
Chem. 1990, 29, 985–988.
1-[3′-(N,N-Diethylaminomethyl)benzyl]-4,7,10-tris(carbam-
oylmethyl)-1,4,7,10-tetraazacyclododecane (4). Bromoacetamide
(0.60 g, 4.32 mmol), compound 10 (0.50 g, 1.44 mmol) and K2CO3
(25) Zhang, X.; Chang, C. A.; Brittain, H. G.; Garrison, J. M.; Telser, J.;
Tweedle, M. F. Inorg. Chem. 1992, 31, 5597–5600.
(26) Epstein, D. M.; Chappell, L. L.; Khalili, H.; Supkowski, R. M.;
Horrocks, W. D., Jr.; Morrow, J. R. Inorg. Chem. 2000, 39, 2130–
2134.
(27) Supkowski, R. M.; Horrocks, W. D. Inorg. Chem. 1999, 38, 5616–
5619.
(30) Le Baccon, M.; Chuburu, F.; Toupet, L.; Handel, H.; Soibinet, M.;
Dechamps-Olivier, I.; Barbier, J.-P.; Aplincourt, M. New J. Chem.
2001, 25, 1168–1174.
(31) Xia, C.-Q.; Jiang, N.; Zhang, J.; Chen, S.-Y.; Lin, H.-H.; Tan, X.-Y.;
Yue, Y.; Yu, X.-Q. Bioorg. Med. Chem. 2006, 14, 5756–5764.
(28) Farquhar, E. R.; Richard, J. P.; Morrow, J. R. Inorg. Chem. 2007, 46,
7169–7177.
(29) Brown, D. M.; Usher, D. A. J. Chem. Soc. 1965, 6558–6564.
9
14862 J. AM. CHEM. SOC. VOL. 130, NO. 44, 2008